SMDC and CAR-T Combination to Overcome Tumor Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including CAR-T cell therapy, face challenges such as inactivation of cytotoxic lymphocytes in the tumor microenvironment and the presence of immunosuppressive cancer-associated fibroblasts, leading to reduced efficacy and potential off-target toxicity.
Innovation Solution
A combination of small molecule drug conjugates (SMDCs) and chimeric antigen receptor-expressing cytotoxic lymphocytes is administered, where SMDCs include specific drug moieties and linkers to enhance lymphocyte potency and target immunosuppressive cells, while CAR-expressing lymphocytes are engineered to recognize cancer-specific antigens, thereby augmenting treatment efficacy and reducing off-target toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cell therapy is administered alone, then cytotoxic lymphocytes can recognize cancer-specific antigens, but the lymphocytes become inactivated in the tumor microenvironment due to immunosuppressive cancer-associated fibroblasts
Solution Approach 1:
The patent combines CAR-T cell therapy with small molecule drug conjugates that specifically target and eliminate cancer-associated fibroblasts. This merging of two therapeutic approaches (immunotherapy and targeted chemotherapy) creates a synergistic effect where the CAR-T cells are protected from immunosuppression while the fibroblasts are eliminated, thereby maintaining lymphocyte activity and enhancing overall anti-tumor efficacy
Solution Approach 2:
The small molecule drug conjugates act as intermediaries that bridge the gap between the CAR-T cells and the tumor microenvironment. These conjugates specifically target cancer-associated fibroblasts, disrupting their immunosuppressive function and creating a more favorable environment for CAR-T cell activity without directly affecting the lymphocytes themselves
2Reliability
If small molecule drug conjugates are used to target immunosuppressive cells, then lymphocyte potency is enhanced, but off-target toxicity may occur
Solution Approach 1:
The small molecule drug conjugates are designed with high specificity for cancer-associated fibroblasts, concentrating the therapeutic effect locally at the tumor site. The ligand portion of the conjugate binds specifically to receptors overexpressed on fibroblasts, ensuring that the cytotoxic drug is delivered primarily to the target cells while minimizing exposure and toxicity to healthy off-target tissues
Solution Approach 2:
The patent optimizes the parameters of the small molecule drug conjugates, including the choice of ligand, drug moiety, and linker, to achieve the desired balance between efficacy and toxicity. By carefully selecting and adjusting these parameters, the conjugates achieve high specificity for cancer-associated fibroblasts while maintaining an acceptable safety profile with reduced off-target effects
3Productivity
If combination therapy is administered, then cytotoxicity and efficacy are increased, but treatment complexity increases
Solution Approach 1:
The small molecule drug conjugates are administered to pre-treat the tumor microenvironment and eliminate cancer-associated fibroblasts before the CAR-T cells are infused. This preliminary action creates a more favorable environment for the subsequent CAR-T cell therapy, reducing the burden on the lymphocytes to navigate through immunosuppressive barriers and thereby simplifying the overall treatment approach while maintaining high efficacy
Data Source
AI summary
A method of treating a cancer in a subject comprising administering to the subject (i) a small molecule drug conjugate (SMDC), which targets a cell-surface receptor on an immunosuppressive cell or a cancerous cell, and (ii) cytotoxic lymphocytes, which express a chimeric antigen receptor (CAR); and synergistic combinations of a SMDC and CAR-expressing cytotoxic lymphocytes.